Isotretinoin for Proliferative Vitreoretinopathy

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wills Eye
• Treatments: Isotretinoin

Criteria

Inclusion Criteria:

• 18-70 year-old men or 50-70 year-old, post-menopausal women.

• Healthy enough to participate in the study.

• Willing and able to consent to participation.

• Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or

• Primary RD (retinal detachment) associated with one or more high-risk features

Exclusion Criteria:

• History of hypersensitivity to isotretinoin.

• Current use of a corticosteroid (excluding topical).

• Any history of depression, anorexia, liver or pancreatic disease.

• More than one prior surgical RD repair.

• Patients with closed funnel retinal detachments.

• Patients with chronic retinal detachment, defined as longer than 12 weeks.

• Any use an oral retinoid within 6 months.

• Systemic chemotherapy within 6 months.

• Patients taking supplemental vitamin A.

• Corneal opacity sufficient to impair surgical view.

• Proliferative diabetic retinopathy.